ReviewInternational journal of molecular medicine2026
FGFR1 signaling in rheumatoid arthritis: Mechanisms of bone destruction and therapeutic targeting (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is an inflammatory, systematic and articular autoimmune disease characterized by progressive cartilage degradation and bone erosion, leading to irreversible joint deformity. Fibroblast growth factor receptor 1 (FGFR1) is a key mediator of RA‑associated bone loss. Within inflamed joints, FGFR1 expression is markedly upregulated in synovial fibroblasts, osteoclasts and chondrocytes. Ligand engagement drives receptor dimerization and kinase activation, activating PI3K/Akt, MAPK and STAT signaling cascades that amplify cytokine release, matrix metalloproteinase expression and osteoclastogenesis. These converging signals promote cartilage degradation and cortical bone erosion, fueling progressive deformity. Targeting FGFR1 markedly attenuates bone loss and disease severity in both murine and humanized models. The present review aimed to summarize the potential of FGFR1 as a tractable therapeutic node for RA bone destruction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.